{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T05:59:53Z","timestamp":1780898393680,"version":"3.54.1"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Refractory or corticosteroid-dependent juvenile generalized myasthenia gravis (gMG) remains a clinical challenge, given the scarcity of available regimens and prominent corticosteroid-related adverse effects. Telitacicept, a dual inhibitor of B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), has demonstrated efficacy in adult gMG, whereas clinical data in pediatric patients remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the clinical response, tolerability, and potential corticosteroid-sparing benefit of telitacicept in juvenile refractory gMG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We report one new case of juvenile refractory gMG treated with telitacicept and review three previously reported pediatric gMG cases. Collective analysis was performed to evaluate key outcomes, including changes in Myasthenia Gravis Activities of Daily Living (MG-ADL) score, Quantitative Myasthenia Gravis (QMG) score, corticosteroid dose reduction, and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the index case, telitacicept reduced the MG-ADL score from 3 to 0 and the QMG score from 10 to 3 by week 12. By week 32, the MG-ADL score remained at 0, while the QMG score further decreased to 2, accompanied by a 41.6% reduction in corticosteroid dose. The patient developed mild injection-site erythema and pruritus on only one occasion, which resolved spontaneously. She also had a mild upper respiratory tract infection that resolved within one week following symptomatic treatment. Collective analysis of the four included patients (age range: 7\u201317 years) showed that three cases (Cases 1, 2, and 4) achieved marked improvement (\u22653-point reduction in the MG-ADL score) at 3 months. By 5\u20136 months, all patients presented sustained clinical improvement with a \u22652-point reduction in the MG-ADL score. No severe adverse events were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Telitacicept may be of clinical value and well-tolerated, and may exert a corticosteroid-sparing benefit in juvenile refractory gMG, providing preliminary real\u2212world clinical observations for this understudied population. Further large-scale prospective studies are warranted to confirm these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1857027","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T05:36:19Z","timestamp":1780896979000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Telitacicept in refractory juvenile generalized myasthenia gravis: a case report and collective analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Yanhong","family":"Sun","sequence":"first","affiliation":[{"name":"Neurology Department, Children\u2019s Hospital Affiliated to Shandong University","place":["Jinan, Shandong, China"]},{"name":"Neurology Department, Jinan Children\u2019s Hospital","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiling","family":"Liu","sequence":"additional","affiliation":[{"name":"Neurology Department, Children\u2019s Hospital Affiliated to Shandong University","place":["Jinan, Shandong, China"]},{"name":"Neurology Department, Jinan Children\u2019s Hospital","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Neurology Department, Children\u2019s Hospital Affiliated to Shandong University","place":["Jinan, Shandong, China"]},{"name":"Neurology Department, Jinan Children\u2019s Hospital","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Ma","sequence":"additional","affiliation":[{"name":"Neurology Department, Children\u2019s Hospital Affiliated to Shandong University","place":["Jinan, Shandong, China"]},{"name":"Neurology Department, Jinan Children\u2019s Hospital","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.834212","article-title":"The epidemiology and phenotypes of ocular manifestations in childhood and juvenile myasthenia gravis: a review","volume":"13","author":"Heckmann","year":"2022","journal-title":"Front Neurol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.1971.tb53222.x","article-title":"Studies in myasthenia gravis: revision of a classification","volume":"183","author":"Osserman","year":"1971","journal-title":"Ann N Y Acad Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419832242","article-title":"Understanding the burden of refractory myasthenia gravis","volume":"12","author":"Schneider-Gold","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.31083\/RN47260","article-title":"Progress in the treatment of refractory myasthenia gravis","volume":"81","author":"Liu","year":"2026","journal-title":"Rev Neurol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/08923973.2021.1973493","article-title":"Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease","volume":"43","author":"Shi","year":"2021","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01591-1","article-title":"Telitacicept: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"B8","doi-asserted-by":"publisher","first-page":"S1384","DOI":"10.1212\/WNL.0000000000213885","article-title":"Efficacy and safety of telitacicept in patients with generalized myasthenia gravis: results of a phase 3 study","volume":"104","author":"Yin","year":"2025"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241251476","article-title":"Effectiveness and safety of telitacicept for refractory generalized myasthenia gravis: a retrospective study","volume":"17","author":"Lin","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1752245","article-title":"Telitacicept for refractory AChR-positive generalized myasthenia gravis: a retrospective real-world study","volume":"17","author":"Rong","year":"2026","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2025.1501500","article-title":"Successful treatment of generalized myasthenia gravis with telitacicept: a Chinese case series and literature review","volume":"16","author":"Song","year":"2025","journal-title":"Front Neurol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-12036-y","article-title":"Refractory generalized myasthenia gravis treated successfully with telitacicept: two cases report","volume":"271","author":"Zhang","year":"2024","journal-title":"J Neurol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1549034","article-title":"Telitacicept as an alternative to non-steroidal immunosuppressive therapies in the treatment of myasthenia gravis: a study on clinical efficacy and steroid-sparing effect","volume":"16","author":"Fang","year":"2025","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2026.110696","article-title":"Efficacy and safety of telitacicept for myasthenia gravis in real-world practice and exploratory outcomes in the elderly subgroup","volume":"285","author":"Xiao","year":"2026","journal-title":"Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S493923","article-title":"The latest progress in the application of telitacicept in autoimmune diseases","volume":"18","author":"Liu","year":"2024","journal-title":"Drug Des Devel Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202509260","article-title":"Single-cell immune profiling reveals neutrophils promote myasthenia gravis exacerbation through BAFF secretion","volume":"12","author":"Zhang","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112140-20240731-00537","article-title":"Efficacy and safety of rituximab in the treatment of pediatric myasthenia gravis","volume":"62","author":"Tong","year":"2024","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000200288","article-title":"Rituximab therapy in the treatment of juvenile myasthenia gravis: the French experience","volume":"98","author":"Molimard","year":"2022","journal-title":"Neurology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1857027\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T05:36:20Z","timestamp":1780896980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1857027\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":18,"alternative-id":["10.3389\/fimmu.2026.1857027"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1857027","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"article-number":"1857027"}}